<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00237471</url>
  </required_header>
  <id_info>
    <org_study_id>2004.116</org_study_id>
    <secondary_id>GEENA</secondary_id>
    <nct_id>NCT00237471</nct_id>
  </id_info>
  <brief_title>Impact of Tight Glycaemic Control in Acute Myocardial Infarction</brief_title>
  <official_title>Impact of Tight Glycaemic Control With Insulin on Novel Vascular Disease Risk Factors and Myocardial Function and Perfusion in Acute Myocardial Infarction Patients With Hyperglycaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melbourne Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Melbourne Health</source>
  <brief_summary>
    <textblock>
      To determine whether tight glycaemic control with insulin improves myocardial function and
      myocardial perfusion (measured by myocardial contrast echocardiography) and novel vascular
      risk factors in patients with acute myocardial infarction and hyperglycaemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will randomise patients with acute myocardial infarction and blood glucose levels (BGLs)
      &gt;=10mmol/L within 24 hours of pain onset, to either tight glucose control (aiming BGLs 4.5 -
      7mmol/L) with an insulin infusion (for 24 hours) followed by subcutaneous insulin or standard
      control (BGL 6 - 12mmol/L) without the use of an insulin infusion. Serial myocardial contrast
      echocardiography will measure changes in myocardial perfusion and function from baseline to 3
      months between each group. We will also measure changes in inflammatory and endothelial
      markers over this time to see whether tight glucose control improves these surrogate
      endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    difficulty recruiting patients
  </why_stopped>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the change in wall motion score index between admission, day 3-5 and after 3 months in the two treatment arms.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory/endothelial markers and myocardial perfusion from admission, day 3-5 and after 3 months between the two treatment arms</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Myocardial Infarct</condition>
  <condition>Hyperglycemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin (tight blood glucose control)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;=18years

          -  Acute Myocardial Infarction

          -  Blood Glucose Level &gt;=10mmol/L

          -  Wall motion abnormality on baseline echocardiogram

        Exclusion Criteria:

          -  Active infection/inflammation

          -  Cardiac shunt

          -  Cognitive Impairment

          -  Insulin allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leo Rando, MBBS FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2005</study_first_submitted>
  <study_first_submitted_qc>October 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2005</study_first_posted>
  <last_update_submitted>July 19, 2011</last_update_submitted>
  <last_update_submitted_qc>July 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Leo Rando</name_title>
    <organization>Royal Melbourne Hospital</organization>
  </responsible_party>
  <keyword>Acute Myocardial Infarction</keyword>
  <keyword>Hyperglycaemia</keyword>
  <keyword>Insulin Infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

